Glucose Basi

Glucose Basi is an intravenous (IV) solution that contains glucose as its sole active ingredient. Marketed in the European Union, this product is supplied as a sterile liquid for infusion, without a specified strength, and is used primarily as an energy source or excipient in clinical settings.

Glucose Basi is employed in a variety of clinical situations where rapid carbohydrate delivery is required. It serves as a source of energy, supports parenteral nutrition, and can be used to correct low blood sugar levels.

- Provides an immediate source of glucose for patients unable to eat orally. - Used as a component of total parenteral nutrition (TPN) regimens. - Administered to treat or prevent hypoglycemia during surgery or critical care. - Acts as a diluent for certain intravenous medications. - Utilized in diagnostic procedures that require a glucose load, such as glucose tolerance testing. - Supports metabolic needs during prolonged fasting or severe illness.

Glucose Basi may cause a range of reactions, most of which are related to its glucose content and the intravenous route of administration.

Common: - Transient hyperglycemia or elevated blood glucose levels. - Local irritation or pain at the infusion site. - Mild nausea or vomiting. - Headache or dizziness. - Fluid overload in patients receiving large volumes.

Serious: - Severe hyperglycemia leading to osmotic diuresis. - Anaphylactic or severe allergic reaction. - Electrolyte disturbances, particularly hyponatremia. - Acute pulmonary edema in susceptible individuals. - Sepsis related to contamination of the IV solution.

When using Glucose Basi, clinicians should observe several safety measures to minimize risks. Patient monitoring and assessment are essential before and during infusion.

- Verify blood glucose levels prior to administration and monitor throughout therapy. - Use caution in patients with diabetes mellitus or known hyperglycemia. - Adjust infusion rates in individuals with renal or cardiac insufficiency to avoid fluid overload. - Ensure aseptic technique to prevent contamination and infection. - Review electrolyte status, especially sodium and potassium, before infusion. - Consider alternative carbohydrate sources for patients with known glucose intolerance. - Store the solution according to manufacturer guidelines to maintain sterility.

Glucose Basi can interact with other medications or clinical conditions, influencing its safety and effectiveness.

Avoid: - Co-administration with high-concentration hyperosmolar solutions that may increase the risk of phlebitis. - Simultaneous infusion of insulin without appropriate glucose monitoring. - Use in patients receiving large volumes of dextrose-containing fluids without adjusting total carbohydrate load.

Use with caution: - Diuretics that may alter fluid and electrolyte balance. - Beta‑blockers, which can mask signs of hypoglycemia. - Corticosteroids, which may exacerbate hyperglycemia. - Medications that affect renal function, such as ACE inhibitors. - Nutritional supplements that contain additional sugars or carbohydrates.